Toll Like Receptor 8 (CD288 or TLR8) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Toll Like Receptor 8 (CD288 or TLR8) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • March 2022 •
  • 121 pages •
  • Report ID: 6267470 •
  • Format: PDF
Toll Like Receptor 8 (CD288 or TLR8) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary
According to the recently published report ’Toll Like Receptor 8 - Drugs In Development, 2022’; Toll Like Receptor 8 (CD288 or TLR8) pipeline Target constitutes close to 35 molecules. Out of which approximately 34 molecules are developed by companies and remaining by the universities/institutes.

Toll Like Receptor 8 (CD288 or TLR8) - Toll-like receptor 8 is a protein encoded by the TLR8 gene. It controls host immune response against pathogens through recognition of molecular patterns specific to microorganisms. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response.

The report ’Toll Like Receptor 8 - Drugs In Development, 2022’ outlays comprehensive information on the Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 11, 7, 12 and 3 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecule, respectively.

Report covers products from therapy areas Oncology, Immunology, Infectious Disease and Musculoskeletal Disorders which include indications Solid Tumor, Colorectal Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Systemic Lupus Erythematosus, Hepatitis B, Melanoma, Metastatic Melanoma, Non-Small Cell Lung Cancer, Triple-Negative Breast Cancer (TNBC), Bladder Cancer, Gastric Cancer, Autoimmune Disorders, Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Cervical Cancer, Cutaneous Lupus Erythematosus, Fibrosis, Gastroesophageal (GE) Junction Carcinomas, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer), Merkel Cell Carcinoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Nasopharyngeal Cancer, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Prostate Cancer, Renal Cell Carcinoma, Sarcomas, Soft Tissue Sarcoma, Squamous Cell Carcinoma, Transitional Cell Cancer (Urothelial Cell Cancer), Unspecified Cancer, Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Anal Cancer, Arthritis, Chondrosarcoma, Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE), Colon Cancer, Coronavirus Disease 2019 (COVID-19), Coronavirus Disease 2019 (COVID-19) Pneumonia, Cutaneous T-Cell Lymphoma, Endometrial Cancer, Esophageal Cancer, Ewing Sarcoma, Head And Neck Cancer, Hepatocellular Carcinoma, Hypopharyngeal Cancer, Inflammation, Kaposi Sarcoma, Laryngeal Cancer, Leiomyosarcoma, Leukemia, Medullary Thyroid Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Mycosis Fungoides, Neuroendocrine Tumors, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Osteoarthritis, Osteosarcoma, Pancreatic Cancer, Penile Cancer, Pleomorphic Liposarcoma, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Rheumatoid Arthritis, Sicca Syndrome (Sjogren), Small-Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer, Subacute Cutaneous Lupus Erythematosus (SCLE), Synovial Sarcoma, Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
- The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 8 (CD288 or TLR8)
- The report reviews Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics and enlists all their major and minor projects
- The report assesses Toll Like Receptor 8 (CD288 or TLR8)) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics

Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Toll Like Receptor 8 (CD288 or TLR8)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Toll Like Receptor 8 (CD288 or TLR8) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Loading...

We are very sorry, but an error occurred.
Please contact [email protected] if the problem remains.